Xolair 150 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FCRL1
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $78,961
Award facts
- Contract value 100% obligated
- $78,961.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $78,961 delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Xolair 150 mg/ml syringes. The delivery order, issued on November 28, 2025, with an ultimate completion date of December 19, 2025, utilizes firm fixed-price pricing with no set-aside designation. This award is issued under DMS Pharmaceutical Group's recently established Indefinite Delivery Contract (SPE2DR) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy designed to streamline pharmaceutical procurement for Department of Defense healthcare operations.
The PPV-G GEN V contract, awarded to DMS Pharmaceutical Group on November 13, 2025, carries a ceiling value of $499,999,999 and extends through December 31, 2036, encompassing a 30-month base period with three 30-month option periods. Under this prime vendor framework, DMS Pharmaceutical Group is authorized to supply a comprehensive range of pharmaceutical products including branded and generic medications, biologics, vaccines, and medical consumables to support military healthcare facilities worldwide. Xolair (omalizumab), a biologic immunosuppressant used in allergy and asthma treatment, represents one of the specialized pharmaceutical products within the vendor's established portfolio supporting federal military medical requirements.
Quick answers
Who was awarded contract SPE2DR26FCRL1?
SPE2DR26FCRL1 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 28, 2025.
How much is contract SPE2DR26FCRL1 worth?
The government has obligated $78,961 on SPE2DR26FCRL1.
Is contract SPE2DR26FCRL1 an order under another contract?
Yes. SPE2DR26FCRL1 is a delivery order under SPE2DR25D9168, an indefinite delivery contract.
Was contract SPE2DR26FCRL1 competed?
The extent of competition for SPE2DR26FCRL1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award